Antibody Drug Conjugate
A targeted cancer therapy that chemically links a monoclonal antibody to a potent cytotoxic drug, so the antibody delivers the toxin directly to tumor cells while sparing healthy tissue. These complex biologics are a fast-growing oncology drug class.
What is an Antibody Drug Conjugate?
An Antibody Drug Conjugate (ADC) is a targeted cancer therapy that joins three parts into a single molecule: a monoclonal antibody chosen to recognize a marker on tumor cells, a potent cell-killing drug known as the payload, and a chemical linker that connects the two. The antibody acts as a guidance system, carrying the toxic payload specifically toward cancer cells.
Once the antibody binds its target and is taken inside the tumor cell, the linker releases the cytotoxic drug where it can do its work. The goal is to concentrate a powerful toxin at the tumor while limiting exposure to healthy tissue, something a conventional chemotherapy delivered throughout the body cannot do as selectively.
Why do Antibody Drug Conjugates matter?
ADCs aim to widen the gap between a drug's benefit and its toxicity, allowing the use of payloads far too potent to give on their own. This targeted delivery has made them one of the fastest-expanding categories in oncology drug development.
Designing an effective ADC is technically demanding, because the antibody, linker, and payload must all behave correctly together for the therapy to be both safe and effective. Their complexity is reflected in manufacturing, cost, and the specialized handling these biologics require.
- adc
- antibody-drug conjugate
- what is an antibody drug conjugate
- adc cancer therapy
- antibody drug conjugate definition
- adc drug meaning
- monoclonal antibody conjugate